Citizen Petitions Face Strict Certification Requirements Under FDA Final Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will reject petitions that do not include exact language for certification and verification; hedge fund manager files citizen petition opposing approval of Neoprobe's Lymphoseek.
You may also be interested in...
Biosimilars Added To FDA’s Citizen Petition Certification Program
Agency estimates it will receive 26 certifications for citizen petitions that could potentially delay biosimilar or generic applications and one certification for a petition for stay of agency action.
Citizen Petitions: FDA Sees Increase In Requests For Reconsideration, Serial Filings
FDA is concerned that the number of citizen petitions requesting reconsideration of agency decisions, the filing of serial petitions by the same firm, and requests from non-innovator companies could delay the approval of generics.
FDA Will Summarily Deny Petitions Submitted Solely To Block ANDA Approvals
Draft guidance in implementation of FDAAA provision outlines how FDA will weed out and deny petitions “with a primary purpose of delaying approval of an application.”.